Zoster Eye Disease Study (ZEDS) - March 2021
The Zoster Eye Disease Study (ZEDS), a NEI/NIH supported double-masked placebo-controlled clinical trial to determine whether 1 year of suppressive valacyclovir treatment reduces complications of Herpes Zoster Ophthalmicus, including eye disease and/or postherpetic neuralgia. At a recent DSMC meeting it was recommended that we work with optometrists to increase enrollment. A list of current active Participating Clinical Centers (PCC) can be found below. There are approximately 80 centers, including 70 across the United States, 9 in Canada and 1 in New Zealand. We are not adding new centers. We hope very much that optometrists will refer their HZO patients who are immunocompetent, have a history of a typical HZO rash anytime in the past, and a record of an episode of active keratitis or iritis within the past year to our centers for possible enrollment.
This is a wonderful opportunity for our professions to work together to promote science and public health by developing a high-quality evidence-based new standard of care to improve outcomes in HZO. I am happy to provide you with additional information and answer any questions.
Elisabeth J. Cohen, MD
Professor of Ophthalmology,
NYU Grossman School of Medicine, NYU Langone Health
View Active PCC List